Professional
Added to YB: 2026-09-17
Pitch date: 2026-06-30
DIVISLAB.NS [bullish]
Divi's Laboratories Limited
Author Info
No bio for this author
Company Info
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally.
Market Cap
INR 2.5T
Pitch Price
N/A
Price Target
N/A
Dividend
0.32%
EV/EBITDA
61.58
P/E
84.58
EV/Sales
21.75
Sector
Life Sciences Tools and Services
Category
growth
Baron Emerging Markets Fund Added On Portfolio Holding: Divi's Laboratories Limited
DIVISLAB.NS (added to position): The position was increased on Divi’s expected benefit from pharmaceutical customers diversifying API sourcing away from China and its onboarding by large global companies into oral and injectable GLP-1 supply chains. Complex-intermediate and custom-peptide manufacturing should provide multiyear revenue visibility as GLP-1 demand expands; supported by capacity expansion and sustained R&D, Divi’s is expected to deliver mid-teens compound revenue growth and 20% earnings growth over three to five years.
Read full article (1 min)